The Key Role and Potential Molecular Mechanism of HER2 (ERBB2) in Breast Cancer: A Bioinformatics Analysis Based on the TCGA-BRCA Database.
DOI:
https://doi.org/10.54097/45bpq965Keywords:
ERBB2; Breast Cancer; Bioinformatics Analysis; Protein–Protein Interaction Network; Functional Enrichment Analysis.Abstract
Breast cancer is one of the most common malignant tumors in women, with the HER2-positive subtype exhibiting strong invasiveness and poor prognosis. ERBB2, a key encoding gene of HER2, plays a crucial role in the development and progression of breast cancer, and its molecular mechanisms still require further in-depth analysis. This study, based on the TCGA-BRCA database, integrated transcriptome expression data, clinical information, and survival data to comprehensively analyze the molecular characteristics related to ERBB2. Differential expression analysis identified 334 significantly expressed genes, and GO and Hallmark pathway analyses revealed that they are mainly involved in the ERBB2 signaling pathway, estrogen response, and lipid metabolism. Further PPI network construction and module analysis revealed that ERBB2, GRB7, STARD3, PGAP3, and MIEN1 form a highly cohesive core functional module. Based on survival analysis, there is some correlation between ERBB2 expression and patient survival. The present study sheds lights on the synergistic interactions between ERBB2 and co-amplified genes in breast cancer, indicating that they may be involved in the synergistic progression of breast cancer and metabolic reprogramming. The results serve as a reference for the research of molecular mechanism of breast cancer that is positive to the HER2 receptor and screening for potential targets, but there is no experiment verification. Future studies could integrate multi-omics with functional experiments to further confirm the function of important genes and to study related molecular mechanisms.
Downloads
References
[1] Giaquinto AN, Sung H, Miller KD, Kramer JL, Newman LA, Minihan A, Jemal A, Siegel RL. Breast Cancer Statistics, 2022. CA Cancer J Clin. 2022 Nov;72(6):524-541. doi: 10.3322/caac.21754. Epub 2022. PMID: 36190501. DOI: https://doi.org/10.3322/caac.21754
[2] Marchiò C, Annaratone L, Marques A, Casorzo L, Berrino E, Sapino A. Evolving concepts in HER2 evaluation in breast cancer: Heterogeneity, HER2-low carcinomas and beyond. Semin Cancer Biol. 2021 Jul;72:123-135. doi: 10.1016/j.semcancer.2020.02.016. Epub 2020. PMID: 32112814. DOI: https://doi.org/10.1016/j.semcancer.2020.02.016
[3] Kunte S, Abraham J, Montero AJ. Novel HER2-targeted therapies for HER2-positive metastatic breast cancer. Cancer. 2020 Oct 1;126(19):4278-4288. doi: 10.1002/cncr.33102. Epub 2020. PMID: 32721042. DOI: https://doi.org/10.1002/cncr.33102
[4] DeBusk K, Abeysinghe S, Vickers A, Nangia A, Bell J, Ike C, Forero-Torres A, Blahna MT. Efficacy of tucatinib for HER2-positive metastatic breast cancer after HER2-targeted therapy: a network meta-analysis. Future Oncol. 2021 Nov;17(33):4635-4647. doi: 10.2217/fon-2021-0742. Epub 2021. PMID: 34463120. DOI: https://doi.org/10.2217/fon-2021-0742
[5] Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235(4785):177-82. doi: 10.1126/science.3798106. PMID: 3798106. DOI: https://doi.org/10.1126/science.3798106
[6] Raghav KPS, Moasser MM. Molecular Pathways and Mechanisms of HER2 in Cancer Therapy. Clin Cancer Res. 2023;29(13):2351-2361. doi: 10.1158/1078-0432.CCR-22-0283. PMID: 36574481; PMCID: PMC10293474. DOI: https://doi.org/10.1158/1078-0432.CCR-22-0283
[7] Pal SK, Pegram M. Targeting HER2 Epitopes. Semin Oncol. 2006;33(4):386-91. doi: 10.1053/j.seminoncol.2006.04.004. PMID: 16890794. DOI: https://doi.org/10.1053/j.seminoncol.2006.04.004
[8] Kauraniemi P, Kallioniemi A. Activation of multiple cancer-associated genes at the ERBB2 amplicon in breast cancer. Endocr Relat Cancer. 2006;13(1):39-49. doi: 10.1677/erc.1.01147. PMID: 16601278. DOI: https://doi.org/10.1677/erc.1.01147
[9] Provenzano L, Dieci MV, Curigliano G, Giuliano M, Botticelli A, Lambertini M, Rizzo G, Pedersini R, Sirico M, La Verde N, Gennari A, Zambelli A, Toss A, Piras M, Giordano M, Tagliaferri B, Generali D, Sartori D, Miliziano D, Menichetti A, Ligorio F, Zurlo C, Griguolo G, Berton Giachetti PP, Faso V, Corti C, Chiappe E, Scagnoli S, Pisegna S, Capasso C, De Angelis C, Arpino G, Criscitiello C, Guarneri V, Pruneri G, Mariani L, Vernieri C; PALMARES-2 Study Group. Real-world effectiveness comparison of first-line palbociclib, ribociclib or abemaciclib plus endocrine therapy in advanced HR-positive/HER2-negative BC patients: results from the multicenter PALMARES-2 study. Ann Oncol. 2025;36(7):762-774. doi: 10.1016/j.annonc.2025.03.023. Epub 2025. PMID: 40204155. DOI: https://doi.org/10.1016/j.annonc.2025.03.023
[10] Cucciniello L, Garufi G, Di Rienzo R, Martinelli C, Pavone G, Giuliano M, Arpino G, Montemurro F, Del Mastro L, De Laurentiis M, Puglisi F. Estrogen deprivation effects of endocrine therapy in breast cancer patients: Incidence, management and outcome. Cancer Treat Rev. 2023;120:102624. doi: 10.1016/j.ctrv.2023.102624. Epub 2023. PMID: 37751658. DOI: https://doi.org/10.1016/j.ctrv.2023.102624
Downloads
Published
Issue
Section
License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

